Expression and clinical significance of inhibitor of apoptosis protein Survivin in children with acute leukemia
Fan Yan-fen
Abstract
Fan Yan-fen
Abstract
Objective To investigate the expression and clinical significance of inhibitor of apoptosis protein Survivin in children with acute leukemia(AL).Methods Among 49 patients with AL,26 cases were diagnosed first time and weren't treated,23 cases were complete remission after treatment.The expression of Survivin protein was detected by immunohistochemical assay in 49 children with AL and 10 children without malignant blood disease.Results Survivin protein positive expression rate in 26 newly diagnosed children with AL(65.38%)is significantly higher than that in complete remission children(17.39%)and the children in control group(10.00%,P0.017).There is no significant difference in the positive expression of Survivin between the newly diagnosed acute lymphoblastic leukemia(63.16%)and acute myeloblastic leukemiapatients(71.43%,P0.05).Conclusion Survivin may participate in the pathogenesis and progress of AL by inhibiting the apoptosis of tumor cell.It provides a new strategy for the therapy of AL in children.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To investigate the expression and clinical significance of inhibitor of apoptosis protein Survivin in children with acute leukemia(AL).Methods Among 49 patients with AL,26 cases were diagnosed first time and weren't treated,23 cases were complete remission after treatment.The expression of Survivin protein was detected by immunohistochemical assay in 49 children with AL and 10 children without malignant blood disease.Results Survivin protein positive expression rate in 26 newly diagnosed children with AL(65.38%)is significantly higher than that in complete remission children(17.39%)and the children in control group(10.00%,P0.017).There is no significant difference in the positive expression of Survivin between the newly diagnosed acute lymphoblastic leukemia(63.16%)and acute myeloblastic leukemiapatients(71.43%,P0.05).Conclusion Survivin may participate in the pathogenesis and progress of AL by inhibiting the apoptosis of tumor cell.It provides a new strategy for the therapy of AL in children.
Key concepts: Survivin, Acute myeloblastic leukemia, Inhibitor of apoptosis, Medicine, Apoptosis, Pathogenesis, Acute leukemia, Immunohistochemistry